INFI Stock Overview
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer.
+ 1 more risk
Infinity Pharmaceuticals, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.15|
|52 Week High||US$3.89|
|52 Week Low||US$0.46|
|1 Month Change||75.57%|
|3 Month Change||114.03%|
|1 Year Change||-62.90%|
|3 Year Change||-5.74%|
|5 Year Change||15.00%|
|Change since IPO||-92.58%|
Recent News & Updates
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|INFI||US Biotechs||US Market|
Return vs Industry: INFI underperformed the US Biotechs industry which returned -23% over the past year.
Return vs Market: INFI underperformed the US Market which returned -11.7% over the past year.
|INFI Average Weekly Movement||19.8%|
|Biotechs Industry Average Movement||12.5%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: INFI is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 20% a week.
Volatility Over Time: INFI's weekly volatility has increased from 14% to 20% over the past year.
About the Company
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
Infinity Pharmaceuticals, Inc. Fundamentals Summary
|INFI fundamental statistics|
Is INFI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|INFI income statement (TTM)|
|Cost of Revenue||US$32.98m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.52|
|Net Profit Margin||-2,110.33%|
How did INFI perform over the long term?See historical performance and comparison